4.6
2.2
| Citation: |
Weixi Feng, Yanli Zhang, Peng Sun, Ming Xiao. Acquired immunity and Alzheimer's disease[J]. The Journal of Biomedical Research, 2023, 37(1): 15-29. DOI: 10.7555/JBR.36.20220083
|
Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in head and neck cancers. In 2018 alone, there were approximately 129 000 recorded NPC cases with 73 000 NPC-related deaths worldwide[1]. NPC generally responds to radiotherapy and chemotherapy, with radiotherapy being to frontline therapy for NPC. In recent years, the development of intensity-modulated radiotherapy (IMRT) has substantially improved the locoregional control rate for NPC patients. However, distant metastasis constitutes the primary cause of treatment failure[2]. Indeed, even after definitive chemoradiotherapy, 15%–30% of non-metastatic NPC cases develop distal metastasis[3–5].
Conventionally, distant metastases are considered an incurable systemic element of disease progression which is generally treated using palliative approaches. The National Comprehensive Cancer Network (NCCN) guidelines recommend platinum-based palliative chemotherapy (PCT) for metastatic NPC. First-line chemotherapeutics studies have highlighted a median survival for metastatic NPC patients ranging from 12.1 to 22.1 months[6–8]. However, metastatic disease comprises a broad spectrum of characteristics and prognosis. Hellman and Weichselbaum proposed the concept of "oligometastases", whereby oligometastatic diseases spread to specific organs despite initially having a limited capacity to do so[9]. Therefore, localized treatments may be effective within the primary foci or metastatic lesions. In the past few years, local treatments for metastatic NPC have become the focus of interest for many researchers. For example, a randomized phase Ⅲ study found that locoregional radiotherapy targeting primary tumors and metastatic lymph nodes following chemotherapy, significantly improves survival among chemo-sensitive patients with synchronous metastatic NPC[10]. Additionally, several retrospective studies have shown that local treatment of metastases can improve survival in patients with metastatic NPC[11–13]. Although, existing studies have not identified suitable candidates for local treatment in metastatic NPC.
Lacking an established standard for treating metastatic NPC may be due to the fact that there is no consensus around risk. Metastatic NPC patients are not an homogeneous group of people and there are within and between individual differences in terms of responses to treatment. This creates a whole host of unknown and there are, very few prospective studies which have assessed localized treatments of metastatic lesions. Therefore, we cannot confer survival benefits associated with each treatment modality for patients with metastatic NPC. It is reasonable to suggest that an individualized predictive model is needed to disentangle factors related to survival and it may then be possible to develop more individualized treatment strategies. Here, we developed a prognostic nomogram to identify NPC patients with metachronous metastasis, who would benefit most from local treatments.
Data from 347 NPC patients were collated and retrospectively reviewed. All patients had been diagnosed with metastatic NPC at the Affiliated Cancer Hospital of Nanjing Medical University (China) between January 2006 and December 2020. Patients were considered eligible according to the following criteria: (1) patients with histopathologically confirmed primary NPC; (2) those who had received locoregional radiotherapy with IMRT; and (3) those who had metachronous metastatic disease diagnosed more than 6 months after initial diagnosis[14–15].
Patients were excluded if they had: (1) synchronous metastatic disease; (2) or a Karnofsky Performance Score of <70 when diagnosed with distant metastasis; (3) other malignancies; (4) incomplete clinical or survival data; or (5) those who refused antitumor treatment(s). The 8th edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) system was implemented to restage patients. The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Research Ethics Committee of Jiangsu Cancer Hospital (Approval No. 2021-020), and individual consent for this retrospective study was not deemed necessary.
During the initial treatment period, all patients received radical IMRT to the nasopharynx and neck using simultaneous integrated boost with 6 MV X-ray radiation in our center. Pretreatment assessments included physical examination, electrocardiogram, chest X-ray, as well as hematologic and biochemical profiling.
An abnormal elevation in Epstein-Barr virus (EBV) DNA was considered a factor signifying potential disease relapse. One hundred and eighteen patients underwent EBV DNA detection pretreatment. Pathological analysis of metastatic lesions was established as the gold standard for diagnosing metastases. When pathological findings were unavailable, diagnosis was based on a multimodality imaging system, which included contrast-enhanced computed tomography (CT) of the chest and abdomen, whole-body bone scans, and positron emission tomography (PET-CT).
The total of metastatic lesions was calculated according to image findings, of which 1–5 lesions were defined as oligometastic. More than five lesions was defined as polymetastatic. Locoregional recurrence was confirmed using fiberoptic endoscopy of the nasopharynx and magnetic resonance imaging (MRI) scans of the head and neck.
All patients received PCT according to previous chemotherapy regimens and toxicity tolerance after first distant failure. The median PCT cycles was four, ranging from 1 to 12. PCT regimens included platinum plus 5-fluorouracil, taxane plus platinum, taxane plus platinum with 5-fluorouracil, and gemcitabine plus platinum (GP).
After receiving chemotherapy, 146 patients received local treatment for metastatic lesions, while the remaining patients did not. One or more localized treatments were administered to these patients of whom 16 underwent surgery (1, 11, and 4 cases with liver, lung, and distant lymphatic metastasis, respectively). One hundred and thirty-one patients received radiotherapy for one or more metastatic lesions of whom five received radiofrequency ablation for liver metastases.
Among the patients who received radiotherapy, 19 received stereotactic body radiosurgery (SBRT), including seven with liver metastases and 12 with lung metastases. Radiation doses ranged from 30 to 66 Gy (2–10 Gy/fraction), with a median biologically effective dose of 60 Gy (range: 35–100).
Follow-ups were arranged every three months for the first 2 years and then every 6 to 12 months thereafter, until death or the last follow-up date (June 30, 2021). During the follow-up period, nasopharyngoscopy, contrast-enhanced MRI of nasopharynx and neck, and contrast-enhanced CT of chest and abdomen were performed. PET-CT was considered if necessary. The disease-free interval (DFI) was calculated using the date of initial NPC diagnosis until the diagnosis of distant metastasis. OS was considered, the primary endpoint of this study and was calculated from the date of diagnosis of metastasis to the date of last follow-up or death.
SPSS version 22.0 (IBM, USA) was used to perform statistical analysis. All variables are categorical, and intergroup comparisons were performed using Pearson's chi-squared test or Fisher's test. Cox's proportional hazard model was implemented to investigate the independence of prognostic factors related to OS. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) are reported as effect estimates. Variables that met the predetermined significance threshold (P<0.1) under univariable analysis were entered into multivariable analysis. Two-tailed P<0.05 were considered statistically significant.
R software (version 4.0.3) was used for model building. The prognostic nomogram was constructed using the "rms" package with independent prognostic factors[16]. The "nomogramFormula" package calculated scores for each variable as well as a total score for each patient[17]. The "nomogramEX" package was used to extract formulas from the nomogram[18]. The concordance index (C-index) and calibration curves were used to assess model performance. Kaplan-Meier curves were used to estimate the 1-, 3-, and 5-year OS rates and differences between groups of patients.
A total of 240 NPC patients with metachronous metastasis were considered eligible (Fig. 1). All patients had histologically confirmed non-keratinizing NPC at initial diagnosis. The median age was 49 years (range: 11–78), and 78.8% of this sample were male. 32.5% (n=78) of this sample developed distant metastasis within 12 months following the primary diagnosis (DFI≤12 months). The remaining patients developed distant metastasis after 12 months (DFI>12 months).
The incidence of lung, bone, liver, and distant nodal metastasis was 42.5%, 47.5%, 28.3%, and 28.3%, respectively. Oligometastatic disease was detected in 60.4% (n=145) patients (63 with single metastatic lesions and 82 with 2 to 5 lesions). 39.6% (n=95) patients had polymetastatic disease (>5 lesions). 13.8% (n=33) had simultaneous locoregional recurrence. One hundred and twenty (50%) patients received ≥4 cycles of PCT after the first distant failure, and the remainder received <4 cycles. Demographics and the clinical characteristics of patients with metastatic NPC have been summarized and are provided in Table 1.
| (n [%]) | ||||
| Characteristics | Total patients (n=240) | LT+PCT (n=146) | PCT (n=94) | P- value |
| Age (years) a | 0.202 | |||
| <49 | 117 (48.8) | 76 (52.1) | 41 (43.6) | |
| ≥49 | 123 (51.2) | 70 (47.9) | 53 (56.4) | |
| Sex | 0.104 | |||
| Female | 51 (21.2) | 26 (17.8) | 25 (26.6) | |
| Male | 189 (78.8) | 120 (82.2) | 69 (73.4) | |
| BMI | 0.653 | |||
| <23 | 109 (45.4) | 68 (46.6) | 41 (43.6) | |
| ≥23 | 131 (54.6) | 78 (53.4) | 53 (56.4) | |
| KPS | 0.644 | |||
| ≤80 | 104 (43.3) | 65 (44.5) | 39 (41.5) | |
| >80 | 136 (56.7) | 81 (55.5) | 55 (58.5) | |
| T stageb | 0.126 | |||
| T1 | 27 (11.3) | 11 (7.5) | 16 (17.0) | |
| T2 | 43 (17.9) | 27 (18.5) | 16 (17.0) | |
| T3 | 75 (31.2) | 50 (34.2) | 25 (26.6) | |
| T4 | 95 (39.6) | 58 (39.8) | 37 (39.4) | |
| N stageb | 0.940 | |||
| N0 | 3 (1.2) | 2 (1.4) | 1 (1.1) | |
| N1 | 77 (32.1) | 48 (32.9) | 29 (30.9) | |
| N2 | 109 (45.4) | 64 (43.8) | 45 (47.9) | |
| N3 | 51 (21.3) | 32 (21.9) | 19 (20.1) | |
| DFI (months) | 0.682 | |||
| ≤12 | 78 (32.5) | 46 (31.5) | 32 (34.0) | |
| >12 | 162 (67.5) | 100 (68.5) | 62 (66.0) | |
| Lung metastasis | <0.001 | |||
| No | 138 (57.5) | 98 (67.1) | 40 (42.6) | |
| Yes | 102 (42.5) | 48 (32.9) | 54 (57.4) | |
| Bone metastasis | <0.001 | |||
| No | 126 (52.5) | 61 (41.8) | 65 (69.1) | |
| Yes | 114 (47.5) | 85 (58.2) | 29 (30.9) | |
| Liver metastasis | 0.001 | |||
| No | 172 (71.7) | 116 (79.5) | 56 (59.6) | |
| Yes | 68 (28.3) | 30 (20.5) | 38 (40.4) | |
| Distant nodal metastasis | <0.001 | |||
| No | 165 (68.8) | 115 (78.8) | 50 (53.2) | |
| Yes | 75 (31.2) | 31 (21.2) | 44 (46.8) | |
| No. of metastatic lesions | <0.001 | |||
| 1 | 63 (26.2) | 50 (34.3) | 13 (13.8) | |
| 2–5 | 82 (34.2) | 50 (34.2) | 32 (34.0) | |
| >5 | 95 (39.6) | 46 (31.5) | 49 (52.2) | |
| Pretreatment EBV DNA | 0.148 | |||
| Undetectable | 49 (20.4) | 35 (24.0) | 14 (14.9) | |
| Detectable | 69 (28.8) | 37 (25.3) | 32 (34.0) | |
| Not available | 122 (50.8) | 74 (50.7) | 48 (51.1) | |
| Locoregional recurrence | 0.051 | |||
| No | 207 (86.2) | 131 (89.7) | 76 (80.9) | |
| Yes | 33 (13.8) | 15 (10.3) | 18 (19.1) | |
| No. of PCT cycles | 0.002 | |||
| <4 | 120 (50.0) | 85 (58.2) | 35 (37.2) | |
| ≥4 | 120 (50.0) | 61 (41.8) | 59 (62.8) | |
| aAge at diagnosis of distant metastasis. bAccording to the 8th UICC/AJCC staging system. LT: local treatment of metastases; PCT: palliative chemotherapy; BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; EBV: Epstein-Barr virus; No.: number. | ||||
DownLoad:
CSV
The median follow-up duration was 23 months (ranging from 1 to 176 months). 169 patients died during this study period. The 1-, 3-, and 5-year OS rates were 76.1%, 39.8%, and 24.8%, respectively.
The results of univariable and multivariable regression analysis are provided in Table 2. Six variables were considered statistically significant intergroup differences, including sex, DFI, liver metastasis, number of metastatic lesions, locoregional recurrence, and number of PCT cycles. These variables were identified as independent prognostic factors for OS in metastatic NPC patients. Specifically, being female was associated with a better prognosis (HR=1.690; 95% CI: 1.095–2.542; P=0.012).
| Variables | Univariable | Multivariable | |||
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age (years)a | |||||
| <49 | Reference | ||||
| ≥49 | 1.137 (0.839–1.542) | 0.407 | |||
| Sex | |||||
| Female | Reference | Reference | |||
| Male | 1.484 (1.009–2.182) | 0.045 | 1.690 (1.124–2.542) | 0.012 | |
| BMI | |||||
| <23 | Reference | ||||
| ≥23 | 0.991 (0.732–1.342) | 0.952 | |||
| KPS | |||||
| ≤80 | Reference | ||||
| >80 | 0.918 (0.677–1.244) | 0.580 | |||
| T stageb | |||||
| T1 | Reference | ||||
| T2 | 1.057 (0.602–1.857) | 0.847 | |||
| T3 | 0.847 (0.507–1.415) | 0.526 | |||
| T4 | 0.722 (0.436–1.196) | 0.206 | |||
| N stageb | |||||
| N0 | Reference | ||||
| N1 | 3.265 (0.451–23.624) | 0.241 | |||
| N2 | 3.572 (0.496–25.717) | 0.206 | |||
| N3 | 4.840 (0.663–35.327) | 0.120 | |||
| DFI (months) | |||||
| ≤12 | Reference | Reference | |||
| >12 | 0.604 (0.442–0.825) | 0.001 | 0.650 (0.466–0.908) | 0.012 | |
| Lung metastasis | |||||
| No | Reference | Reference | |||
| Yes | 0.754 (0.554–1.025) | 0.072 | 0.848 (0.580–1.239) | 0.394 | |
| Bone metastasis | |||||
| No | Reference | Reference | |||
| Yes | 1.397 (1.033–1.890) | 0.030 | 0.895 (0.612–1.310) | 0.569 | |
| Liver metastasis | |||||
| No | Reference | Reference | |||
| Yes | 1.737 (1.261–2.393) | 0.001 | 1.580 (1.113–2.243) | 0.011 | |
| Distant nodal metastasis | |||||
| No | Reference | Reference | |||
| Yes | 1.659 (1.210–2.276) | 0.002 | 0.866 (0.579–1.295) | 0.483 | |
| No. of metastatic lesions | |||||
| 1 | Reference | Reference | |||
| 2–5 | 1.746 (1.115–2.736) | 0.015 | 2.875 (1.749–4.725) | <0.001 | |
| >5 | 4.713 (3.052–7.279) | <0.001 | 7.955 (4.597–13.766) | <0.001 | |
| Locoregional recurrence | |||||
| No | Reference | Reference | |||
| Yes | 1.473 (0.974–2.229) | 0.067 | 2.079 (1.338–3.230) | 0.001 | |
| No. of PCT cycles | |||||
| <4 | Reference | Reference | |||
| ≥4 | 0.630 (0.465–0.853) | 0.003 | 0.403 (0.281–0.576) | <0.001 | |
| aAge at diagnosis of distant metastasis. bAccording to the 8th UICC/AJCC staging system. BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; No.: number; PCT: palliative chemotherapy; HR: hazard ratio; CI: confidence interval. | |||||
DownLoad:
CSV
Patients who developed distant metastasis within 12 months after the primary diagnosis (DFI≤12) generally had poorer prognosis (HR=0.650; 95% CI: 0.466–0.908; P=0.012). Concerning the site of metastasis, liver metastasis (HR=1.580; 95% CI: 1.113–2.243; P=0.011) was an adverse prognostic factor for survival. The number of metastatic lesions had a profound impact on clinical outcomes compared to those with single lesions. Patients with 2 to 5 or more than 5 lesions had a significantly poorer prognosis (HR=2.875; 95% CI: 1.749–4.725 and HR=7.955; 95% CI: 4.597–13.766; both P<0.001).
Concurrent locoregional recurrence with distant metastasis conferred an increased mortality risk (HR=2.079; 95% CI: 1.338–3.230; P=0.001). Additionally, patients who received ≥4 cycles of PCT experienced significantly improved OS than compared to those with <4 cycles (HR=0.403; 95% CI: 0.281–0.576; P<0.001).
Based on the predictors derived through multivariable regression analysis, a prognostic nomogram was constructed to predict the 1-, 3-, and 5-year survival (Fig. 2). In order to use the nomogram, each variable subtype had to correspond with score on a specific point scale. The total score was then calculated using scores which corresponded to each variable, to estimate the 1-, 3-, and 5-year OS rates (Supplementary Table 1, available online). Nomogram formulas for generating OS probabilities were calculated, as follows:
1-year OS=1.54e−07×points^3−9.34e−05×points^2+0.012 174 368×points+0.443 082 846
3-year OS=1.54e−07×points^3−5.7954e−05× points^2+0.000 544 564×points+0.896 856 023
5-year OS=2.81e−07×points^3−7.6778e−05× points^2−1.627 6e−05×points+0.825 548 036
The C-index of the nomogram was 0.764 (95% CI: 0.649–0.806), which suggests good accuracy for predicting survival. Calibration curves obtained using the bootstrap method showed good fitness between predicted and observed survival (Fig. 3).
We used the median total score from the prognostic nomogram to stratify the cohort into the low- (risk score 0–122) and high-risk (risk score 123–260) groups (Table 3). Baseline characteristics of low- and high-risk patients have been provided in the Supplementary Tables 2 and 3 (available online), respectively. The 1-, 3-, and 5-year OS rates of patients in each group are also summarized in Supplementary Table 4 (available online).
| Variable | Low-risk (n=116) | High-risk (n=124) | P-value |
| Age (years)a | 0.240 | ||
| <49 | 52 (44.8) | 65 (52.4) | |
| ≥49 | 64 (55.2) | 59 (47.6) | |
| Sex | 0.020 | ||
| Female | 32 (27.6) | 19 (15.3) | |
| Male | 84 (72.4) | 105 (84.7) | |
| BMI | 0.390 | ||
| <23 | 56 (48.3) | 53 (42.7) | |
| ≥23 | 60 (51.7) | 71 (57.3) | |
| KPS | 0.330 | ||
| ≤80 | 54 (46.6) | 50 (40.3) | |
| >80 | 62 (53.4) | 74 (59.7) | |
| T stageb | 0.852 | ||
| T1 | 11 (9.5) | 16 (1.9) | |
| T2 | 21 (18.1) | 22 (17.7) | |
| T3 | 38 (32.8) | 37 (29.8) | |
| T4 | 46 (39.6) | 49 (39.6) | |
| N stageb | 0.530 | ||
| N0 | 2 (1.7) | 1 (0.8) | |
| N1 | 41 (35.3) | 36 (29.0) | |
| N2 | 52 (44.8) | 57 (46.0) | |
| N3 | 21 (18.2) | 30 (24.2) | |
| DFI (months) | 0.034 | ||
| ≤12 | 30 (25.9) | 48 (38.7) | |
| >12 | 86 (74.1) | 76 (61.3) | |
| Lung metastasis | 0.219 | ||
| No | 62 (53.4) | 76 (61.3) | |
| Yes | 54 (46.6) | 48 (38.7) | |
| Bone metastasis | 0.009 | ||
| No | 71 (61.2) | 55 (44.4) | |
| Yes | 45 (38.8) | 69 (55.6) | |
| Liver metastasis | 0.005 | ||
| No | 93 (80.2) | 79 (63.7) | |
| Yes | 23 (19.8) | 45 (36.3) | |
| Distant nodal metastasis | <0.001 | ||
| No | 96 (82.8) | 69 (55.6) | |
| Yes | 20 (17.2) | 55 (44.4) | |
| No. of metastatic lesions | <0.001 | ||
| 1 | 60 (51.7) | 3 (2.4) | |
| 2–5 | 53 (45.7) | 29 (23.4) | |
| >5 | 3 (2.6) | 92 (74.2) | |
| Locoregional recurrence | 0.138 | ||
| No | 104 (89.7) | 103 (83.1) | |
| Yes | 12 (10.3) | 21 (16.9) | |
| No. of PCT cycles | <0.001 | ||
| <4 | 44 (37.9) | 76 (61.3) | |
| ≥4 | 72 (62.1) | 48 (38.7) | |
| aAge at diagnosis of distant metastasis. bAccording to the 8th UICC/AJCC staging system. BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; No.: number; PCT: palliative chemotherapy; LT: local treatment of metastases. | |||
DownLoad:
CSV
Kaplan-Meier curves for OS highlighted significant intergroup differences (P<0.001; Fig. 4), which also suggests this model is effective at stratifying metastatic NPC patients. With an estimated median OS of 45.0 months, the 1-, 3-, and 5-year OS rates of patients in the low-risk group were 93.6%, 60.0%, and 41.1% respectively, which were all significantly higher than the OS rates observed in high-risk patients (median OS: 15.0 months; 1-, 3-, and 5-year OS rates: 59.4%, 18.8%, and 6.4%). The nomogram remained a clinically and statistically significant prognostic model when this sample was stratified according to age (≥49 or <49 years), sex (female or male), T stage (T1–2 or T3–4), and N stage (N0–1 or N2–3) (Supplementary Fig. 1, available online).
To select patients who might benefit from local treatment of metastases, we further compared OS for patients with or without local treatment and within each risk group. For low-risk patients who received PCT plus local treatment or PCT alone, the 1-, 3-, and 5-year OS rates were 94.9%, 67.3%, 57.0%, and 91.9%, 53.1%, 21.7%, respectively (P=0.009, Fig. 5A). In the high-risk group, the 1-, 3-, and 5-year OS rates of patients with or without local treatment were 56.2%, 18.9%, 7.2%, and 63.2%, 18.8%, 5.6%, respectively (P=0.927, Fig. 5B).
According to multivariable analysis (Table 4), patients in the low-risk group, who received PCT plus local treatment, had a significantly better prognosis than those who received PCT alone (HR=0.570; 95% CI: 0.343–0.947; P=0.030). However, there was no significant intergroup difference in terms of survival between the two treatment groups in the high-risk group (HR=0.994; 95% CI: 0.678–1.458; P=0.975).
| Variable | Low-risk | High-risk | |||
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Treatment (LT+PCT vs. PCT) | 0.570 (0.343–0.947) | 0.030 | 0.994 (0.678–1.458) | 0.975 | |
| Risk score | 1.018 (1.007–1.028) | 0.001 | 1.022 (1.014–1.029) | <0.001 | |
| LT: local treatment of metastases; PCT: palliative chemotherapy; HR: hazard ratio; CI: confidence interval. | |||||
DownLoad:
CSV
Significant progress has been made in localized controls for NPC due to the development of IMRT and imaging systems which are now more precise at defining tumors and identifying organs at risk. However, distant metastases are still a challenge for patients with NPC, and there is no consensus regarding treatment strategies. According to the GEM20110714 study[7], the preferred first-line regimen of GP in metastatic NPC resulted in a median OS of 22.1 months and 1-, 3-, and 5-year OS rates of 79.9%, 31.8%, and 19.2%, respectively. However, prognosis for metastatic NPC patients has significant heterogeneity in the real world due to the broad spectrum of metastatic diseases and the use of various treatments. In this study, we established an easy-to-use nomogram for predicting OS for patients with metastatic NPC. This novel model appears to perform well at identifying candidates who would benefit from local treatments.
According to the NCCN guidelines, systemic chemotherapy remains the cornerstone of the therapeutic management of metastatic NPC patients. Consistent with previous reports[19–20], this study showed that patients who received more than 4 cycles of PCT had a significantly longer overall survival compared to those administered with fewer than four cycles. However, adequate chemotherapy does not mean that the course of chemotherapy should be extended indefinitely. Numerous reports have proposed that appropriate local treatment could improve the local control of metastatic lesions and confers survival benefits on some patients. For example Huang et al[11] reported that NPC patients with limited liver metastases treated by a partial hepatectomy achieved a median OS of 45.2 months, which was obviously elevated compared to 14.1 months in the control group. Likewise in patients with lung-only metastases from NPC, pulmonary metastasectomy provided reliable local control and survival benefits with significantly higher 5-year survival rates than in the nonsurgically treated group (75.5% vs. 47.8%, P=0.005)[21]. A retrospective studies also revealed that chemoradiotherapy conferred a better prognosis than chemotherapy alone in NPC patients with bone metastases[22–23].
In clinical practice, however, not all metastatic lesions of NPC will respond to local treatments. Based on the nomogram we established in this study, patients with metastatic NPC were stratified into low- and high-risk groups. We found that the survival benefit associated with local treatment which was solely observed in those considered at low-risk. There was no additional survival benefit in high-risk patients receiving local treatment compared with PCT alone. This may explain why local treatment did not demonstrate a statistically significant difference in OS across the entire cohort and further demonstrates the validity of our model. Therefore, clinicians can use our model to determine who responds best to local treatment and make individualized treatment recommendations. Our study fills the gap where previous studies failed to identify who would benefit from local treatment of metastases. Increasingly, evidence suggests that applying, potentially curative metastasis-directed radiotherapy for oligometastatic disease in various solid tumors, significantly improves survival and was associated with low treatment-related toxicity[24–27]. Due to the advancement of radiotherapeutic technologies, such as SBRT, ablative radiotherapy doses can be safely delivered to sites of metastasis. Regrettably, only 19 patients in our study underwent SBRT for metastatic lesions, and the sample size was too small for further analysis.
The definition of oligometastatic NPC has been widely discussed, and the generally accepted definition notes the presence of up to five metastatic lesions on imaging. In the present study, multivariable Cox regression indicated that the number of metastatic lesions was the most decisive prognostic parameter. Consistent with results reported in previous studies[20,28–29], the prognosis of patients with oligometastatic disease (1-5 lesions) is significantly better than that for those with polymetastatic disease (>5 lesions). The presence of a single lesion predicted superior survival outcomes than that of multiple metastatic lesions, possibly because a single lesion is more amenable to radical local treatment in the clinic. It is worth noting that we only included patients with metachronous metastatic disease or what is commonly referred to as post-treatment metastasis. Unlike those with synchronous metastatic NPC, patients with metachronous metastasis have already received aggressive radiotherapy to the primary foci. In the present study, concurrent locoregional recurrence was identified as a poor prognostic factor for metastatic NPC. Locoregional recurrent NPC after initial radiotherapy is likely to be radioresistant. Besides, an uncontrolled primary tumor may promote distant metastasis. It is currently unclear whether a locoregionally controlled primary tumor should become a precondition for diagnosing the oligometastatic disease, but it should be considered a crucial prognostic parameter for metastatic NPC.
Generally, patients with oligometastatic disease tend to have a low tumor burden and are more likely to receive aggressive metastasis-directed therapy, such as surgery or high-dose irradiation. In contrast, patients with polymetastatic disease are generally considered to have no curative potential and receive palliative systemic therapy. Nonetheless, in our study, not all cases with oligometastases were included in the low-risk group, and a proportion of patients with polymetastatic disease achieved better survival following comprehensive treatment. Metastatic status changes throughout the disease dynamically, and patients with polymetastatic disease may achieve oligometastatic status during successful systemic therapy[14–15]. Moreover, oligometastatic disease is diagnosed solely based on imaging because no biomarker is currently available for identifying patients with oligometastatic disease, in the clinic. However, imaging modalities fail to detect occult metastasis early, and biomarkers to assess tumor burden dynamics for surveillance during and after treatment are needed.
There are several limitations of this study that need to be noted. First, the retrospective study might result in a potential selection bias. Second, as the limitation of sample size and center number, we failed to conduct external validation. Third, only 118 patients in this study cohort underwent pretreatment plasma EBV DNA detection. Thus, it was hard to estimate the potential prognostic value of EBV DNA. Finally, innovations in chemotherapeutic regimens and advances in radiotherapeutic technology have inevitably changed treatment protocols, although the general treatment principles have remained unchanged.
In conclusion, we established an easy-to-use nomogram which demonstrated good performance in predicting survival and provided individualized stratification for patients with metastatic NPC. Using the prognostic model, patients who are sensitive to local treatment can be identified. In the future, multicenter external validation and prospective studies are needed to generalize the use of our model.
This work was supported by the National Natural Science Foundation of China (Grant No. 81872192) and China International Medical Foundation (Grant No. Z-2014-06-19392).
CLC number: R749.16, Document code: A
The authors reported no conflict of interests.
| [1] |
Alzheimer's Association. 2019 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2019, 15(3): 321–387. doi: 10.1016/j.jalz.2019.01.010
|
| [2] |
Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies[J]. Cell, 2019, 179(2): 312–339. doi: 10.1016/j.cell.2019.09.001
|
| [3] |
Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease[J]. Nat Rev Neurol, 2015, 11(8): 457–470. doi: 10.1038/nrneurol.2015.119
|
| [4] |
Xie C, Zhuang X, Niu Z, et al. Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow[J]. Nat Biomed Eng, 2022, 6(1): 76–93. doi: 10.1038/s41551-021-00819-5
|
| [5] |
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease[J]. Lancet Neurol, 2015, 14(4): 388–405. doi: 10.1016/S1474-4422(15)70016-5
|
| [6] |
Ransohoff RM. How neuroinflammation contributes to neurodegeneration[J]. Science, 2016, 353(6301): 777–783. doi: 10.1126/science.aag2590
|
| [7] |
Fang EF, Hou Y, Palikaras K, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease[J]. Nat Neurosci, 2019, 22(3): 401–412. doi: 10.1038/s41593-018-0332-9
|
| [8] |
Lautrup S, Lou G, Aman Y, et al. Microglial mitophagy mitigates neuroinflammation in Alzheimer's disease[J]. Neurochem Int, 2019, 129: 104469. doi: 10.1016/j.neuint.2019.104469
|
| [9] |
Perry VH, Holmes C. Microglial priming in neurodegenerative disease[J]. Nat Rev Neurol, 2014, 10(4): 217–224. doi: 10.1038/nrneurol.2014.38
|
| [10] |
Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease[J]. Nat Rev Neurosci, 2015, 16(6): 358–372. doi: 10.1038/nrn3880
|
| [11] |
Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease[J]. Nat Rev Immunol, 2014, 14(7): 463–477. doi: 10.1038/nri3705
|
| [12] |
Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, et al. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease[J]. Curr Opin Neurobiol, 2016, 36: 74–81. doi: 10.1016/j.conb.2015.10.004
|
| [13] |
Salter MW, Stevens B. Microglia emerge as central players in brain disease[J]. Nat Med, 2017, 23(9): 1018–1027. doi: 10.1038/nm.4397
|
| [14] |
Efthymiou AG, Goate AM. Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk[J]. Mol Neurodegener, 2017, 12(1): 43. doi: 10.1186/s13024-017-0184-x
|
| [15] |
Mhatre SD, Tsai CA, Rubin AJ, et al. Microglial malfunction: the third rail in the development of Alzheimer's disease[J]. Trends Neurosci, 2015, 38(10): 621–636. doi: 10.1016/j.tins.2015.08.006
|
| [16] |
Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease[J]. Cell, 2017, 169(7): 1276–1290.e17. doi: 10.1016/j.cell.2017.05.018
|
| [17] |
Zewinger S, Reiser J, Jankowski V, et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation[J]. Nat Immunol, 2020, 21(1): 30–41. doi: 10.1038/s41590-019-0548-1
|
| [18] |
Osborn LM, Kamphuis W, Wadman WJ, et al. Astrogliosis: an integral player in the pathogenesis of Alzheimer's disease[J]. Prog Neurobiol, 2016, 144: 121–141. doi: 10.1016/j.pneurobio.2016.01.001
|
| [19] |
Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology[J]. Nat Neurosci, 2013, 16(7): 848–850. doi: 10.1038/nn.3435
|
| [20] |
Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease[J]. Lancet Neurol, 2013, 12(1): 92–104. doi: 10.1016/S1474-4422(12)70259-4
|
| [21] |
Deming Y, Filipello F, Cignarella F, et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk[J]. Sci Transl Med, 2019, 11(505): eaau2291. doi: 10.1126/scitranslmed.aau2291
|
| [22] |
Cuyvers E, Sleegers K. Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond[J]. Lancet Neurol, 2016, 15(8): 857–868. doi: 10.1016/S1474-4422(16)00127-7
|
| [23] |
Yuan P, Condello C, Keene CD, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy[J]. Neuron, 2016, 90(4): 724–739. doi: 10.1016/j.neuron.2016.05.003
|
| [24] |
Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury[J]. Sci Transl Med, 2016, 8(369): 369ra178. doi: 10.1126/scitranslmed.aag1767
|
| [25] |
Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models[J]. Science, 2016, 352(6286): 712–716. doi: 10.1126/science.aad8373
|
| [26] |
Riazi K, Galic MA, Kentner AC, et al. Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the hippocampus during peripheral inflammation[J]. J Neurosci, 2015, 35(12): 4942–4952. doi: 10.1523/JNEUROSCI.4485-14.2015
|
| [27] |
Zhang J, Malik A, Choi HB, et al. Microglial CR3 activation triggers long-term synaptic depression in the hippocampus via NADPH oxidase[J]. Neuron, 2014, 82(1): 195–207. doi: 10.1016/j.neuron.2014.01.043
|
| [28] |
Lau SF, Chen C, Fu W, et al. IL-33-PU.1 Transcriptome reprogramming drives functional state transition and clearance activity of microglia in alzheimer's disease[J]. Cell Rep, 2020, 31(3): 107530. doi: 10.1016/j.celrep.2020.107530
|
| [29] |
Huang K, Marcora E, Pimenova AA, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease[J]. Nat Neurosci, 2017, 20(8): 1052–1061. doi: 10.1038/nn.4587
|
| [30] |
Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β[J]. Sci Transl Med, 2012, 4(147): 147ra111. doi: 10.1126/scitranslmed.3003748
|
| [31] |
Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules[J]. J Exp Med, 2015, 212(7): 991–999. doi: 10.1084/jem.20142290
|
| [32] |
Mestre H, Hablitz LM, Xavier AL, et al. Aquaporin-4-dependent glymphatic solute transport in the rodent brain[J]. Elife, 2018, 7: e40070. doi: 10.7554/eLife.40070
|
| [33] |
Ahn JH, Cho H, Kim JH, et al. Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid[J]. Nature, 2019, 572(7767): 62–66. doi: 10.1038/s41586-019-1419-5
|
| [34] |
Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels[J]. Nature, 2015, 523(7560): 337–341. doi: 10.1038/nature14432
|
| [35] |
Wang L, Zhang Y, Zhao Y, et al. Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice[J]. Brain Pathol, 2019, 29(2): 176–192. doi: 10.1111/bpa.12656
|
| [36] |
Da Mesquita S, Louveau A, Vaccari A, et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease[J]. Nature, 2018, 560(7717): 185–191. doi: 10.1038/s41586-018-0368-8
|
| [37] |
Xu Z, Xiao N, Chen Y, et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits[J]. Mol Neurodegener, 2015, 10: 58. doi: 10.1186/s13024-015-0056-1
|
| [38] |
Peng W, Achariyar TM, Li B, et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease[J]. Neurobiol Dis, 2016, 93: 215–225. doi: 10.1016/j.nbd.2016.05.015
|
| [39] |
Busse M, Michler E, von Hoff F, et al. Alterations in the peripheral immune system in dementia[J]. J Alzheimers Dis, 2017, 58(4): 1303–1313. doi: 10.3233/JAD-161304
|
| [40] |
Richartz-Salzburger E, Batra A, Stransky E, et al. Altered lymphocyte distribution in Alzheimer's disease[J]. J Psychiatr Res, 2007, 41(1-2): 174–178. doi: 10.1016/j.jpsychires.2006.01.010
|
| [41] |
Pellicanò M, Larbi A, Goldeck D, et al. Immune profiling of Alzheimer patients[J]. J Neuroimmunol, 2012, 242(1-2): 52–59. doi: 10.1016/j.jneuroim.2011.11.005
|
| [42] |
Bulati M, Buffa S, Martorana A, et al. Double negative (IgG+IgD-CD27-) B cells are increased in a cohort of moderate-severe Alzheimer's disease patients and show a pro-inflammatory trafficking receptor phenotype[J]. J Alzheimers Dis, 2015, 44(4): 1241–1251. doi: 10.3233/JAD-142412
|
| [43] |
Bonotis K, Krikki E, Holeva V, et al. Systemic immune aberrations in Alzheimer's disease patients[J]. J Neuroimmunol, 2008, 193(1-2): 183–187. doi: 10.1016/j.jneuroim.2007.10.020
|
| [44] |
Speciale L, Calabrese E, Saresella M, et al. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients[J]. Neurobiol Aging, 2007, 28(8): 1163–1169. doi: 10.1016/j.neurobiolaging.2006.05.020
|
| [45] |
Larbi A, Pawelec G, Witkowski JM, et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease[J]. J Alzheimers Dis, 2009, 17(1): 91–103. doi: 10.3233/JAD-2009-1015
|
| [46] |
Bulati M, Buffa S, Candore G, et al. B cells and immunosenescence: a focus on IgG+IgD-CD27- (DN) B cells in aged humans[J]. Ageing Res Rev, 2011, 10(2): 274–284. doi: 10.1016/j.arr.2010.12.002
|
| [47] |
Steele NZR, Carr JS, Bonham LW, et al. Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: a case-control study[J]. PLoS Med, 2017, 14(3): e1002272. doi: 10.1371/journal.pmed.1002272
|
| [48] |
Jiang Q, Jin S, Jiang Y, et al. Alzheimer's disease variants with the genome-wide significance are significantly enriched in immune pathways and active in immune cells[J]. Mol Neurobiol, 2017, 54(1): 594–600. doi: 10.1007/s12035-015-9670-8
|
| [49] |
Gate D, Saligrama N, Leventhal O, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease[J]. Nature, 2020, 577(7790): 399–404. doi: 10.1038/s41586-019-1895-7
|
| [50] |
Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms[J]. Trends Immunol, 2005, 26(9): 485–495. doi: 10.1016/j.it.2005.07.004
|
| [51] |
Siffrin V, Brandt AU, Radbruch H, et al. Differential immune cell dynamics in the CNS cause CD4+ T cell compartmentalization[J]. Brain, 2009, 132(Pt 5): 1247–1258. doi: 10.1093/brain/awn354
|
| [52] |
Pranzatelli MR, Allison TJ, McGee NR, et al. Cerebrospinal fluid γδ T cell frequency is age-related: a case-control study of 435 children with inflammatory and non-inflammatory neurological disorders[J]. Clin Exp Immunol, 2018, 193(1): 103–112. doi: 10.1111/cei.13122
|
| [53] |
Cheng X, He P, Yao H, et al. Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy[J]. Neurology, 2014, 82(19): 1707–1715. doi: 10.1212/WNL.0000000000000403
|
| [54] |
Carrano A, Hoozemans JJM, van der Vies SM, et al. Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy[J]. Antioxid Redox Signal, 2011, 15(5): 1167–1178. doi: 10.1089/ars.2011.3895
|
| [55] |
Liu Y, Guo D, Tian L, et al. Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-α-dependent[J]. Neurobiol Aging, 2010, 31(2): 175–188. doi: 10.1016/j.neurobiolaging.2008.03.024
|
| [56] |
Kerfoot SM, Kubes P. Overlapping roles of P-selectin and α4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis[J]. J Immunol, 2002, 169(2): 1000–1006. doi: 10.4049/jimmunol.169.2.1000
|
| [57] |
Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE[J]. Nat Immunol, 2009, 10(5): 514–523. doi: 10.1038/ni.1716
|
| [58] |
Laurent C, Dorothée G, Hunot S, et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy[J]. Brain, 2017, 140(1): 184–200. doi: 10.1093/brain/aww270
|
| [59] |
Smolders J, Remmerswaal EBM, Schuurman KG, et al. Characteristics of differentiated CD8+ and CD4+ T cells present in the human brain[J]. Acta Neuropathol, 2013, 126(4): 525–535. doi: 10.1007/s00401-013-1155-0
|
| [60] |
Togo T, Akiyama H, Iseki E, et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases[J]. J Neuroimmunol, 2002, 124(1-2): 83–92. doi: 10.1016/S0165-5728(01)00496-9
|
| [61] |
Agrawal S, Anderson P, Durbeej M, et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis[J]. J Exp Med, 2006, 203(4): 1007–1019. doi: 10.1084/jem.20051342
|
| [62] |
Song J, Wu C, Korpos E, et al. Focal MMP-2 and MMP-9 activity at the blood-brain barrier promotes chemokine-induced leukocyte migration[J]. Cell Rep, 2015, 10(7): 1040–1054. doi: 10.1016/j.celrep.2015.01.037
|
| [63] |
Betsholtz C. Physiology: double function at the blood-brain barrier[J]. Nature, 2014, 509(7501): 432–433. doi: 10.1038/nature13339
|
| [64] |
Kook SY, Seok Hong H, Moon M, et al. Disruption of blood-brain barrier in Alzheimer disease pathogenesis[J]. Tissue Barriers, 2013, 1(2): e23993. doi: 10.4161/tisb.23993
|
| [65] |
Stamatovic SM, Martinez-Revollar G, Hu A, et al. Decline in Sirtuin-1 expression and activity plays a critical role in blood-brain barrier permeability in aging[J]. Neurobiol Dis, 2019, 126: 105–116. doi: 10.1016/j.nbd.2018.09.006
|
| [66] |
Shechter R, London A, Schwartz M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates[J]. Nat Rev Immunol, 2013, 13(3): 206–218. doi: 10.1038/nri3391
|
| [67] |
Engelhardt B, Wolburg-Buchholz K, Wolburg H. Involvement of the choroid plexus in central nervous system inflammation[J]. Microsc Res Tech, 2001, 52(1): 112–129. doi: 10.1002/1097-0029(20010101)52:1<112::AID-JEMT13>3.0.CO;2-5
|
| [68] |
Choi JD, Moon Y, Kim HJ, et al. Choroid plexus volume and permeability at brain MRI within the alzheimer disease clinical spectrum[J]. Radiology, 2022, 212400. doi: 10.1148/radiol.212400
|
| [69] |
Vargas T, Ugalde C, Spuch C, et al. Aβ accumulation in choroid plexus is associated with mitochondrial-induced apoptosis[J]. Neurobiol Aging, 2010, 31(9): 1569–1581. doi: 10.1016/j.neurobiolaging.2008.08.017
|
| [70] |
Brkic M, Balusu S, Van Wonterghem E, et al. Amyloid β oligomers disrupt blood-CSF barrier integrity by activating matrix metalloproteinases[J]. J Neurosci, 2015, 35(37): 12766–12778. doi: 10.1523/JNEUROSCI.0006-15.2015
|
| [71] |
Schläger C, Körner H, Krueger M, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid[J]. Nature, 2016, 530(7590): 349–353. doi: 10.1038/nature16939
|
| [72] |
Roth TL, Nayak D, Atanasijevic T, et al. Transcranial amelioration of inflammation and cell death after brain injury[J]. Nature, 2014, 505(7482): 223–228. doi: 10.1038/nature12808
|
| [73] |
Barker CF, Billingham RE. The role of afferent lymphatics in the rejection of skin homografts[J]. J Exp Med, 1968, 128(1): 197–221. doi: 10.1084/jem.128.1.197
|
| [74] |
Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system[J]. Nat Rev Immunol, 2012, 12(9): 623–635. doi: 10.1038/nri3265
|
| [75] |
Louveau A, Herz J, Alme MN, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature[J]. Nat Neurosci, 2018, 21(10): 1380–1391. doi: 10.1038/s41593-018-0227-9
|
| [76] |
Rogers J, Luber-Narod J, Styren SD, et al. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease[J]. Neurobiol Aging, 1988, 9(4): 339–349. doi: 10.1016/S0197-4580(88)80079-4
|
| [77] |
Sardi F, Fassina L, Venturini L, et al. Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly[J]. Autoimmun Rev, 2011, 11(2): 149–153. doi: 10.1016/j.autrev.2011.09.005
|
| [78] |
Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease[J]. J Clin Invest, 2003, 112(3): 415–422. doi: 10.1172/JCI200318104
|
| [79] |
Browne TC, McQuillan K, McManus RM, et al. IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease[J]. J Immunol, 2013, 190(5): 2241–2251. doi: 10.4049/jimmunol.1200947
|
| [80] |
Fisher Y, Strominger I, Biton S, et al. Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance[J]. J Immunol, 2014, 192(1): 92–102. doi: 10.4049/jimmunol.1301707
|
| [81] |
Cao C, Arendash GW, Dickson A, et al. Aβ-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS[J]. Neurobiol Dis, 2009, 34(1): 63–70. doi: 10.1016/j.nbd.2008.12.015
|
| [82] |
Asuni AA, Boutajangout A, Scholtzova H, et al. Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages[J]. Eur J Neurosci, 2006, 24(9): 2530–2542. doi: 10.1111/j.1460-9568.2006.05149.x
|
| [83] |
Lambracht-Washington D, Qu B, Fu M, et al. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation[J]. Cell Mol Neurobiol, 2011, 31(6): 867–874. doi: 10.1007/s10571-011-9680-7
|
| [84] |
Fu H, Liu B, Frost JL, et al. Amyloid-β immunotherapy for Alzheimer's disease[J]. CNS Neurol Disord Drug Targets, 2010, 9(2): 197–206. doi: 10.2174/187152710791012017
|
| [85] |
Goldeck D, Larbi A, Pellicanó M, et al. Enhanced chemokine receptor expression on leukocytes of patients with Alzheimer's disease[J]. PLoS One, 2013, 8(6): e66664. doi: 10.1371/journal.pone.0066664
|
| [86] |
Zhang J, Ke K, Liu Z, et al. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of Aβ1–42-induced Alzheimer's disease model rats[J]. PLoS One, 2013, 8(10): e75786. doi: 10.1371/journal.pone.0075786
|
| [87] |
Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity[J]. Brain, 2010, 133(Pt 8): 2232–2247. doi: 10.1093/brain/awq176
|
| [88] |
Alves S, Churlaud G, Audrain M, et al. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice[J]. Brain, 2017, 140(3): 826–842. doi: 10.1093/brain/aww330
|
| [89] |
Dansokho C, Ait Ahmed D, Aid S, et al. Regulatory T cells delay disease progression in Alzheimer-like pathology[J]. Brain, 2016, 139(Pt 4): 1237–1251. doi: 10.1093/brain/awv408
|
| [90] |
Di Liberto G, Pantelyushin S, Kreutzfeldt M, et al. Neurons under T cell attack coordinate phagocyte-mediated synaptic stripping[J]. Cell, 2018, 175(2): 458–471.e19. doi: 10.1016/j.cell.2018.07.049
|
| [91] |
Mattsson N, Andreasson U, Zetterberg H, et al. Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease[J]. JAMA Neurol, 2017, 74(5): 557–566. doi: 10.1001/jamaneurol.2016.6117
|
| [92] |
Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease[J]. Nat Med, 2019, 25(2): 277–283. doi: 10.1038/s41591-018-0304-3
|
| [93] |
Krishnamoorthy G, Saxena A, Mars LT, et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis[J]. Nat Med, 2009, 15(6): 626–632. doi: 10.1038/nm.1975
|
| [94] |
McQuillan K, Lynch MA, Mills KHG. Activation of mixed glia by Aβ-specific Th1 and Th17 cells and its regulation by Th2 cells[J]. Brain Behav Immun, 2010, 24(4): 598–607. doi: 10.1016/j.bbi.2010.01.003
|
| [95] |
Takahashi K, Rochford CDP, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2[J]. J Exp Med, 2005, 201(4): 647–657. doi: 10.1084/jem.20041611
|
| [96] |
Gaikwad S, Larionov S, Wang Y, et al. Signal regulatory protein-β1: a microglial modulator of phagocytosis in Alzheimer's disease[J]. Am J Pathol, 2009, 175(6): 2528–2539. doi: 10.2353/ajpath.2009.090147
|
| [97] |
Obregon D, Hou H, Bai Y, et al. CD40L disruption enhances Aβ vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation[J]. Neurobiol Dis, 2008, 29(2): 336–353. doi: 10.1016/j.nbd.2007.09.009
|
| [98] |
Le Blon D, Guglielmetti C, Hoornaert C, et al. Intracerebral transplantation of interleukin 13-producing mesenchymal stem cells limits microgliosis, oligodendrocyte loss and demyelination in the cuprizone mouse model[J]. J Neuroinflammation, 2016, 13(1): 288. doi: 10.1186/s12974-016-0756-7
|
| [99] |
Guarda G, Dostert C, Staehli F, et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes[J]. Nature, 2009, 460(7252): 269–273. doi: 10.1038/nature08100
|
| [100] |
Garg SK, Banerjee R, Kipnis J. Neuroprotective immunity: T cell-derived glutamate endows astrocytes with a neuroprotective phenotype[J]. J Immunol, 2008, 180(6): 3866–3873. doi: 10.4049/jimmunol.180.6.3866
|
| [101] |
Beurel E, Harrington LE, Buchser W, et al. Astrocytes modulate the polarization of CD4+ T cells to Th1 cells[J]. PLoS One, 2014, 9(1): e86257. doi: 10.1371/journal.pone.0086257
|
| [102] |
Xie L, Choudhury GR, Winters A, et al. Cerebral regulatory T cells restrain microglia/macrophage-mediated inflammatory responses via IL-10[J]. Eur J Immunol, 2015, 45(1): 180–191. doi: 10.1002/eji.201444823
|
| [103] |
Dombrowski Y, O'Hagan T, Dittmer M, et al. Regulatory T cells promote myelin regeneration in the central nervous system[J]. Nat Neurosci, 2017, 20(5): 674–680. doi: 10.1038/nn.4528
|
| [104] |
Aloisi F, De Simone R, Columba-Cabezas S, et al. Functional maturation of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cells[J]. J Immunol, 2000, 164(4): 1705–1712. doi: 10.4049/jimmunol.164.4.1705
|
| [105] |
Das Sarma J, Ciric B, Marek R, et al. Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis[J]. J Neuroinflammation, 2009, 6: 14. doi: 10.1186/1742-2094-6-14
|
| [106] |
Rock RB, Hu S, Deshpande A, et al. Transcriptional response of human microglial cells to interferon-γ[J]. Genes Immun, 2005, 6(8): 712–719. doi: 10.1038/sj.gene.6364246
|
| [107] |
Togo T, Akiyama H, Kondo H, et al. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases[J]. Brain Res, 2000, 885(1): 117–121. doi: 10.1016/S0006-8993(00)02984-X
|
| [108] |
Townsend KP, Town T, Mori T, et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid β-peptide[J]. Eur J Immunol, 2005, 35(3): 901–910. doi: 10.1002/eji.200425585
|
| [109] |
McManus RM, Mills KHG, Lynch MA. T cells-protective or pathogenic in Alzheimer's disease?[J]. J Neuroimmune Pharmacol, 2015, 10(4): 547–560. doi: 10.1007/s11481-015-9612-2
|
| [110] |
Zeinstra E, Wilczak N, De Keyser J. Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7–1 and B7–2[J]. J Neuroimmunol, 2003, 135(1-2): 166–171. doi: 10.1016/S0165-5728(02)00462-9
|
| [111] |
Yang J, Kou J, Lalonde R, et al. Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease[J]. Brain Behav Immun, 2017, 65: 262–273. doi: 10.1016/j.bbi.2017.05.012
|
| [112] |
Weiss R, Lifshitz V, Frenkel D. TGF-β1 affects endothelial cell interaction with macrophages and T cells leading to the development of cerebrovascular amyloidosis[J]. Brain Behav Immun, 2011, 25(5): 1017–1024. doi: 10.1016/j.bbi.2010.11.012
|
| [113] |
Man S, Ma Y, Shang D, et al. Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's disease[J]. Neurobiol Aging, 2007, 28(4): 485–496. doi: 10.1016/j.neurobiolaging.2006.02.013
|
| [114] |
Pietronigro E, Zenaro E, Bianca VD, et al. Blockade of α4 integrins reduces leukocyte-endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer's disease[J]. Sci Rep, 2019, 9(1): 12055. doi: 10.1038/s41598-019-48538-x
|
| [115] |
Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease[J]. Nat Genet, 2010, 42(9): 781–785. doi: 10.1038/ng.642
|
| [116] |
Fuller JP, Stavenhagen JB, Teeling JL. New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease[J]. Front Neurosci, 2014, 8: 235. doi: 10.3389/fnins.2014.00235
|
| [117] |
Piazza F, Greenberg SM, Savoiardo M, et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies[J]. Ann Neurol, 2013, 73(4): 449–458. doi: 10.1002/ana.23857
|
| [118] |
Sollvander S, Ekholm-Pettersson F, Brundin RM, et al. Increased number of plasma B cells producing autoantibodies against Aβ42 protofibrils in Alzheimer's disease[J]. J Alzheimers Dis, 2015, 48(1): 63–72. doi: 10.3233/JAD-150236
|
| [119] |
Maftei M, Thurm F, Schnack C, et al. Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients[J]. PLoS One, 2013, 8(7): e68996. doi: 10.1371/journal.pone.0068996
|
| [120] |
Mimouni D, Gdalevich M, Mimouni FB, et al. Does immune serum globulin confer protection against skin diseases?[J]. Int J Dermatol, 2000, 39(8): 628–631. doi: 10.1046/j.1365-4362.2000.00983.x
|
| [121] |
Bruhns P, Samuelsson A, Pollard JW, et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease[J]. Immunity, 2003, 18(4): 573–581. doi: 10.1016/S1074-7613(03)00080-3
|
| [122] |
Siragam V, Crow AR, Brinc D, et al. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells[J]. Nat Med, 2006, 12(6): 688–692. doi: 10.1038/nm1416
|
| [123] |
Marsh SE, Abud EM, Lakatos A, et al. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function[J]. Proc Natl Acad Sci U S A, 2016, 113(9): E1316–E1325. doi: 10.1073/pnas.1525466113
|
| [124] |
Cribbs DH, Berchtold NC, Perreau V, et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study[J]. J Neuroinflammation, 2012, 9: 179. doi: 10.1186/1742-2094-9-179
|
| [125] |
Prüss H, Höltje M, Maier N, et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment[J]. Neurology, 2012, 78(22): 1743–1753. doi: 10.1212/WNL.0b013e318258300d
|
| [126] |
Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic[J]. Annu Rev Immunol, 2006, 24: 467–496. doi: 10.1146/annurev.immunol.24.021605.090517
|
| [127] |
Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes[J]. Annu Rev Immunol, 1990, 8: 773–793. doi: 10.1146/annurev.iy.08.040190.004013
|
| [128] |
Avalos AM, Ploegh HL. Early BCR events and antigen capture, processing, and loading on MHC class II on B cells[J]. Front Immunol, 2014, 5: 92. doi: 10.3389/fimmu.2014.00092
|
| [129] |
Sonoda KH, Stein-Streilein J. CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance[J]. Eur J Immunol, 2002, 32(3): 848–857. doi: 10.1002/1521-4141(200203)32:3<848::AID-IMMU848>3.0.CO;2-I
|
| [130] |
Tomihara K, Shin T, Hurez VJ, et al. Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction[J]. Aging Cell, 2012, 11(1): 128–138. doi: 10.1111/j.1474-9726.2011.00764.x
|
| [131] |
Xiong L, Xue L, Du R, et al. Single-cell RNA sequencing reveals B cell-related molecular biomarkers for Alzheimer's disease[J]. Exp Mol Med, 2021, 53(12): 1888–1901. doi: 10.1038/s12276-021-00714-8
|
| [132] |
Kim K, Wang X, Ragonnaud E, et al. Therapeutic B-cell depletion reverses progression of Alzheimer's disease[J]. Nat Commun, 2021, 12(1): 2185. doi: 10.1038/s41467-021-22479-4
|
| [133] |
Weber MS, Prod'Homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity[J]. Ann Neurol, 2010, 68(3): 369–383. doi: 10.1002/ana.22081
|
| [134] |
Pierson ER, Stromnes IM, Goverman JM. B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system[J]. J Immunol, 2014, 192(3): 929–939. doi: 10.4049/jimmunol.1302171
|
| [135] |
Desmond DW, Moroney JT, Sano M, et al. Incidence of dementia after ischemic stroke: results of a longitudinal study[J]. Stroke, 2002, 33(9): 2254–2262. doi: 10.1161/01.STR.0000028235.91778.95
|
| [136] |
Mena H, Cadavid D, Rushing EJ. Human cerebral infarct: a proposed histopathologic classification based on 137 cases[J]. Acta Neuropathol, 2004, 108(6): 524–530. doi: 10.1007/s00401-004-0918-z
|
| [137] |
Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function[J]. Immunity, 2015, 42(4): 607–612. doi: 10.1016/j.immuni.2015.04.005
|
| [138] |
Olkhanud PB, Damdinsuren B, Bodogai M, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells[J]. Cancer Res, 2011, 71(10): 3505–3515. doi: 10.1158/0008-5472.CAN-10-4316
|
| [139] |
Minter MR, Main BS, Brody KM, et al. Soluble amyloid triggers a myeloid differentiation factor 88 and interferon regulatory factor 7 dependent neuronal type-1 interferon response in vitro[J]. J Neuroinflammation, 2015, 12: 71. doi: 10.1186/s12974-015-0263-2
|
| [140] |
Bodogai M, Moritoh K, Lee-Chang C, et al. Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B cells[J]. Cancer Res, 2015, 75(17): 3456–3465. doi: 10.1158/0008-5472.CAN-14-3077
|
| [141] |
Sun J, Flach CF, Czerkinsky C, et al. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit[J]. J Immunol, 2008, 181(12): 8278–8287. doi: 10.4049/jimmunol.181.12.8278
|
| [142] |
Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases[J]. Nature, 2014, 507(7492): 366–370. doi: 10.1038/nature12979
|
| [143] |
Matsushita T, Yanaba K, Bouaziz JD, et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression[J]. J Clin Invest, 2008, 118(10): 3420–3430. doi: 10.1172/JCI36030
|
| [144] |
Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population[J]. Nat Immunol, 2010, 11(12): 1093–1101. doi: 10.1038/ni.1952
|
| [145] |
Kurnellas MP, Ghosn EEB, Schartner JM, et al. Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease[J]. Proc Natl Acad Sci U S A, 2015, 112(49): 15016–15023. doi: 10.1073/pnas.1521206112
|
| [146] |
Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization[J]. Neurology, 2003, 61(1): 46–54. doi: 10.1212/01.WNL.0000073623.84147.A8
|
| [147] |
Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report[J]. Nat Med, 2003, 9(4): 448–452. doi: 10.1038/nm840
|
| [148] |
Saresella M, Calabrese E, Marventano I, et al. A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease[J]. Neurobiol Aging, 2012, 33(3): 624.e11–624.e22. doi: 10.1016/j.neurobiolaging.2011.03.004
|
| [149] |
Baruch K, Deczkowska A, Rosenzweig N, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease[J]. Nat Med, 2016, 22(2): 135–137. doi: 10.1038/nm.4022
|
| [150] |
Rosenzweig N, Dvir-Szternfeld R, Tsitsou-Kampeli A, et al. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model[J]. Nat Commun, 2019, 10(1): 465. doi: 10.1038/s41467-019-08352-5
|
| [1] | Dongmei Zhu, Lingli Luo, Hanjie Zeng, Zheng Zhang, Min Huang, Suming Zhou. Knockdown of 11β-hydroxysteroid dehydrogenase type 1 alleviates LPS-induced myocardial dysfunction through the AMPK/SIRT1/PGC-1α pathway[J]. The Journal of Biomedical Research, 2023, 37(4): 290-301. DOI: 10.7555/JBR.36.20220212 |
| [2] | Wang Lei, Zhang Kun, Ding Xin, Wang Yan, Bai Hui, Yang Qing, Ben Jingjing, Zhang Hanwen, Li Xiaoyu, Chen Qi, Zhu Xudong. Fucoidan antagonizes diet-induced obesity and inflammation in mice[J]. The Journal of Biomedical Research, 2021, 35(3): 197-205. DOI: 10.7555/JBR.34.20200153 |
| [3] | Venakatesh Archana G., Mathew Johann J., Coleman Scott, Yang Longqiu, Liu Geoffrey L., Li Marilyn M., Liu Henry. Effects of milrinone on inflammatory response-related gene expressions in cultured rat cardiomyocytes[J]. The Journal of Biomedical Research, 2019, 33(4): 258-263. DOI: 10.7555/JBR.32.20170085 |
| [4] | Alireza Shirpoor, Farzaneh Hosseini Gharalari, Yousef Rasmi, Elaheh Heshmati. Ginger extract attenuates ethanol-induced pulmonary histological changes and oxidative stress in rats[J]. The Journal of Biomedical Research, 2017, 31(6): 521-527. DOI: 10.7555/JBR.31.20160151 |
| [5] | Qin Wei, Yeping Bian, Fuchao Yu, Qiang Zhang, Guanghao Zhang, Yang Li, Songsong Song, Xiaomei Ren, Jiayi Tong. Chronic intermittent hypoxia induces cardiac inflammation and dysfunction in a rat obstructive sleep apnea model[J]. The Journal of Biomedical Research, 2016, 30(6): 490-495. DOI: 10.7555/JBR.30.20160110 |
| [6] | Iyaswamy Ashok, Rathinasamy Sheeladevi, Dapkupar Wankhar. Acute effect of aspartame-induced oxidative stress in Wistar albino rat brain[J]. The Journal of Biomedical Research, 2015, 29(5): 390-396. DOI: 10.7555/JBR.28.20120118 |
| [7] | Guoliang Meng, Jing Wang, Yujiao Xiao, Wenli Bai, Liping Xie, Liyang Shan, Philip K Moore, Yong Ji. GYY4137 protects against myocardial ischemia and reperfusion injury by attenuating oxidative stress and apoptosis in rats[J]. The Journal of Biomedical Research, 2015, 29(3): 203-213. DOI: 10.7555/JBR.28.20140037 |
| [8] | Venkatashivam Shiva Kumar, Anuchandra Ramchandra Rajmane, Mohammad Adil, Amit Dattatraya Kandhare, Pinaki Ghosh, Subhash Laxman Bodhankar. Naringin ameliorates acetic acid induced colitis through modulation of endogenous oxido-nitrosative balance and DNA damage in rats[J]. The Journal of Biomedical Research, 2014, 28(2): 132-145. DOI: 10.7555/JBR.27.20120082 |
| [9] | Ze Guo, Bingrong Zhou, Wei Li, Xuejun Sun, Dan Luo. Hydrogen-rich saline protects against ultraviolet B radiation injury in rats[J]. The Journal of Biomedical Research, 2012, 26(5): 365-371. DOI: 10.7555/JBR.26.20110037 |
| [10] | Bo Cui, Stewart P. Johnson, Nancy Bullock, Francis Ali-Osman, Darell D. Bigner, Henry S. Friedman. Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells[J]. The Journal of Biomedical Research, 2010, 24(6): 424-435. DOI: 10.1016/S1674-8301(10)60057-7 |
Figures(4)
Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail:
info@rhhz.net 
| (n [%]) | ||||
| Characteristics | Total patients (n=240) | LT+PCT (n=146) | PCT (n=94) | P- value |
| Age (years) a | 0.202 | |||
| <49 | 117 (48.8) | 76 (52.1) | 41 (43.6) | |
| ≥49 | 123 (51.2) | 70 (47.9) | 53 (56.4) | |
| Sex | 0.104 | |||
| Female | 51 (21.2) | 26 (17.8) | 25 (26.6) | |
| Male | 189 (78.8) | 120 (82.2) | 69 (73.4) | |
| BMI | 0.653 | |||
| <23 | 109 (45.4) | 68 (46.6) | 41 (43.6) | |
| ≥23 | 131 (54.6) | 78 (53.4) | 53 (56.4) | |
| KPS | 0.644 | |||
| ≤80 | 104 (43.3) | 65 (44.5) | 39 (41.5) | |
| >80 | 136 (56.7) | 81 (55.5) | 55 (58.5) | |
| T stageb | 0.126 | |||
| T1 | 27 (11.3) | 11 (7.5) | 16 (17.0) | |
| T2 | 43 (17.9) | 27 (18.5) | 16 (17.0) | |
| T3 | 75 (31.2) | 50 (34.2) | 25 (26.6) | |
| T4 | 95 (39.6) | 58 (39.8) | 37 (39.4) | |
| N stageb | 0.940 | |||
| N0 | 3 (1.2) | 2 (1.4) | 1 (1.1) | |
| N1 | 77 (32.1) | 48 (32.9) | 29 (30.9) | |
| N2 | 109 (45.4) | 64 (43.8) | 45 (47.9) | |
| N3 | 51 (21.3) | 32 (21.9) | 19 (20.1) | |
| DFI (months) | 0.682 | |||
| ≤12 | 78 (32.5) | 46 (31.5) | 32 (34.0) | |
| >12 | 162 (67.5) | 100 (68.5) | 62 (66.0) | |
| Lung metastasis | <0.001 | |||
| No | 138 (57.5) | 98 (67.1) | 40 (42.6) | |
| Yes | 102 (42.5) | 48 (32.9) | 54 (57.4) | |
| Bone metastasis | <0.001 | |||
| No | 126 (52.5) | 61 (41.8) | 65 (69.1) | |
| Yes | 114 (47.5) | 85 (58.2) | 29 (30.9) | |
| Liver metastasis | 0.001 | |||
| No | 172 (71.7) | 116 (79.5) | 56 (59.6) | |
| Yes | 68 (28.3) | 30 (20.5) | 38 (40.4) | |
| Distant nodal metastasis | <0.001 | |||
| No | 165 (68.8) | 115 (78.8) | 50 (53.2) | |
| Yes | 75 (31.2) | 31 (21.2) | 44 (46.8) | |
| No. of metastatic lesions | <0.001 | |||
| 1 | 63 (26.2) | 50 (34.3) | 13 (13.8) | |
| 2–5 | 82 (34.2) | 50 (34.2) | 32 (34.0) | |
| >5 | 95 (39.6) | 46 (31.5) | 49 (52.2) | |
| Pretreatment EBV DNA | 0.148 | |||
| Undetectable | 49 (20.4) | 35 (24.0) | 14 (14.9) | |
| Detectable | 69 (28.8) | 37 (25.3) | 32 (34.0) | |
| Not available | 122 (50.8) | 74 (50.7) | 48 (51.1) | |
| Locoregional recurrence | 0.051 | |||
| No | 207 (86.2) | 131 (89.7) | 76 (80.9) | |
| Yes | 33 (13.8) | 15 (10.3) | 18 (19.1) | |
| No. of PCT cycles | 0.002 | |||
| <4 | 120 (50.0) | 85 (58.2) | 35 (37.2) | |
| ≥4 | 120 (50.0) | 61 (41.8) | 59 (62.8) | |
| aAge at diagnosis of distant metastasis. bAccording to the 8th UICC/AJCC staging system. LT: local treatment of metastases; PCT: palliative chemotherapy; BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; EBV: Epstein-Barr virus; No.: number. | ||||
DownLoad:
CSV
| Variables | Univariable | Multivariable | |||
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age (years)a | |||||
| <49 | Reference | ||||
| ≥49 | 1.137 (0.839–1.542) | 0.407 | |||
| Sex | |||||
| Female | Reference | Reference | |||
| Male | 1.484 (1.009–2.182) | 0.045 | 1.690 (1.124–2.542) | 0.012 | |
| BMI | |||||
| <23 | Reference | ||||
| ≥23 | 0.991 (0.732–1.342) | 0.952 | |||
| KPS | |||||
| ≤80 | Reference | ||||
| >80 | 0.918 (0.677–1.244) | 0.580 | |||
| T stageb | |||||
| T1 | Reference | ||||
| T2 | 1.057 (0.602–1.857) | 0.847 | |||
| T3 | 0.847 (0.507–1.415) | 0.526 | |||
| T4 | 0.722 (0.436–1.196) | 0.206 | |||
| N stageb | |||||
| N0 | Reference | ||||
| N1 | 3.265 (0.451–23.624) | 0.241 | |||
| N2 | 3.572 (0.496–25.717) | 0.206 | |||
| N3 | 4.840 (0.663–35.327) | 0.120 | |||
| DFI (months) | |||||
| ≤12 | Reference | Reference | |||
| >12 | 0.604 (0.442–0.825) | 0.001 | 0.650 (0.466–0.908) | 0.012 | |
| Lung metastasis | |||||
| No | Reference | Reference | |||
| Yes | 0.754 (0.554–1.025) | 0.072 | 0.848 (0.580–1.239) | 0.394 | |
| Bone metastasis | |||||
| No | Reference | Reference | |||
| Yes | 1.397 (1.033–1.890) | 0.030 | 0.895 (0.612–1.310) | 0.569 | |
| Liver metastasis | |||||
| No | Reference | Reference | |||
| Yes | 1.737 (1.261–2.393) | 0.001 | 1.580 (1.113–2.243) | 0.011 | |
| Distant nodal metastasis | |||||
| No | Reference | Reference | |||
| Yes | 1.659 (1.210–2.276) | 0.002 | 0.866 (0.579–1.295) | 0.483 | |
| No. of metastatic lesions | |||||
| 1 | Reference | Reference | |||
| 2–5 | 1.746 (1.115–2.736) | 0.015 | 2.875 (1.749–4.725) | <0.001 | |
| >5 | 4.713 (3.052–7.279) | <0.001 | 7.955 (4.597–13.766) | <0.001 | |
| Locoregional recurrence | |||||
| No | Reference | Reference | |||
| Yes | 1.473 (0.974–2.229) | 0.067 | 2.079 (1.338–3.230) | 0.001 | |
| No. of PCT cycles | |||||
| <4 | Reference | Reference | |||
| ≥4 | 0.630 (0.465–0.853) | 0.003 | 0.403 (0.281–0.576) | <0.001 | |
| aAge at diagnosis of distant metastasis. bAccording to the 8th UICC/AJCC staging system. BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; No.: number; PCT: palliative chemotherapy; HR: hazard ratio; CI: confidence interval. | |||||
DownLoad:
CSV
| Variable | Low-risk (n=116) | High-risk (n=124) | P-value |
| Age (years)a | 0.240 | ||
| <49 | 52 (44.8) | 65 (52.4) | |
| ≥49 | 64 (55.2) | 59 (47.6) | |
| Sex | 0.020 | ||
| Female | 32 (27.6) | 19 (15.3) | |
| Male | 84 (72.4) | 105 (84.7) | |
| BMI | 0.390 | ||
| <23 | 56 (48.3) | 53 (42.7) | |
| ≥23 | 60 (51.7) | 71 (57.3) | |
| KPS | 0.330 | ||
| ≤80 | 54 (46.6) | 50 (40.3) | |
| >80 | 62 (53.4) | 74 (59.7) | |
| T stageb | 0.852 | ||
| T1 | 11 (9.5) | 16 (1.9) | |
| T2 | 21 (18.1) | 22 (17.7) | |
| T3 | 38 (32.8) | 37 (29.8) | |
| T4 | 46 (39.6) | 49 (39.6) | |
| N stageb | 0.530 | ||
| N0 | 2 (1.7) | 1 (0.8) | |
| N1 | 41 (35.3) | 36 (29.0) | |
| N2 | 52 (44.8) | 57 (46.0) | |
| N3 | 21 (18.2) | 30 (24.2) | |
| DFI (months) | 0.034 | ||
| ≤12 | 30 (25.9) | 48 (38.7) | |
| >12 | 86 (74.1) | 76 (61.3) | |
| Lung metastasis | 0.219 | ||
| No | 62 (53.4) | 76 (61.3) | |
| Yes | 54 (46.6) | 48 (38.7) | |
| Bone metastasis | 0.009 | ||
| No | 71 (61.2) | 55 (44.4) | |
| Yes | 45 (38.8) | 69 (55.6) | |
| Liver metastasis | 0.005 | ||
| No | 93 (80.2) | 79 (63.7) | |
| Yes | 23 (19.8) | 45 (36.3) | |
| Distant nodal metastasis | <0.001 | ||
| No | 96 (82.8) | 69 (55.6) | |
| Yes | 20 (17.2) | 55 (44.4) | |
| No. of metastatic lesions | <0.001 | ||
| 1 | 60 (51.7) | 3 (2.4) | |
| 2–5 | 53 (45.7) | 29 (23.4) | |
| >5 | 3 (2.6) | 92 (74.2) | |
| Locoregional recurrence | 0.138 | ||
| No | 104 (89.7) | 103 (83.1) | |
| Yes | 12 (10.3) | 21 (16.9) | |
| No. of PCT cycles | <0.001 | ||
| <4 | 44 (37.9) | 76 (61.3) | |
| ≥4 | 72 (62.1) | 48 (38.7) | |
| aAge at diagnosis of distant metastasis. bAccording to the 8th UICC/AJCC staging system. BMI: body mass index; KPS: Karnofsky performance score; DFI: disease-free interval; No.: number; PCT: palliative chemotherapy; LT: local treatment of metastases. | |||
DownLoad:
CSV
| Variable | Low-risk | High-risk | |||
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Treatment (LT+PCT vs. PCT) | 0.570 (0.343–0.947) | 0.030 | 0.994 (0.678–1.458) | 0.975 | |
| Risk score | 1.018 (1.007–1.028) | 0.001 | 1.022 (1.014–1.029) | <0.001 | |
| LT: local treatment of metastases; PCT: palliative chemotherapy; HR: hazard ratio; CI: confidence interval. | |||||
DownLoad:
CSV
Authors and Reviewers
